bms hematology pipeline
Previously, Dr. Gottlieb served as the FDAs Deputy Commissioner for Medical and Scientific Affairs and before that, as a Senior Adviser to the Administrator of the Centers for Medicare and Medicaid Services, where he helped advance policies to improve healthcare quality and promote the effective use of new medical technologies. While there, Rich defined the companys scientific vision and built a vibrant research organization, leading a team of multidisciplinary engineers and scientists to build the next generation of automated cell engineering tools. Additionally, the Early Development Program Leadership organization, based here and in Princeton, New Jersey, collaborates across the organization in leading the development and implementation of compelling asset strategies across the portfolio. Our vision is to discover, develop and deliver transformational medicines for patients through our internal discovery efforts and innovative collaborations. BMS at June 2022 oncology and hematology congresses BMS at ACTRIMS Forum 2022 BMS at ECCO 2022 BMS at AHA Scientific Sessions 2021 BMS at ASH 2021 Media Library innovation and partnering are critical drivers of our strategy and have brought significant commercial success and pipeline growth. Here scientists discover and develop medicines in the areas of cancer, immunology, and cardiovascular diseases. She has served as a Senior Advisor at BDT Capital, LLC, a private investment firm, since October, 2017. Prior to joining Agios, Dr. Schenkein was the senior vice president, clinical hematology/oncology at Genentech, where he was responsible for numerous successful oncology drug approvals and leading the medical and scientific strategies for their BioOncology portfolio. His public service since leaving the Senate includes: the 9/11 Commission, advisory board of the Iraq and Afghanistan Veterans Association, co-chair of the Concord Coalition, and the Natural Resources Defense Council. Sandy is also a member of the Boards of Directors of biopharmaceutical companies Idorsia Pharmaceuticals, Aeglea BioTherapeutics, and Flexion Therapeutics. Fully operational since 2009, the site is involved in Target Identification, Lead Discovery and Lead Optimization all the way through to early stage Pharmaceutical Development and Clinical Biomarkers R&D. Learn more about our disclosure commitment. Here, teams examine various aspects of the microenvironment, collaborating closely with discovery and translational scientists across the countryto research how we can harness the bodys own immune system to better target tumors. Phase III - clinical trials investigating the safety and efficacy of an investigational medicine in a larger number of patients who have the disease or condition under study. The building, opened in August 2002, was designed by internationally recognized architect Jean-Paul Viguier. Before Merck, Viet was at Genentech for nearly 10 years where he served in various manufacturing, supply chain, quality assurance and business support leadership roles. This website uses cookies to improve your experience while you navigate through the website. In his prior role at Merck as GM/Site Head, he successfully led the construction, licensure and launch of Mercks first manufacturing site in China. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated. Bristol Myers Squibb is conducting clinical studies across multiple therapeutic areas. Dr. McClellan is a doctor and an economist whose has addressed a wide range of strategies and policy reforms to improve health care, including payment reform to promote better outcomes and lower costs, methods for development and use of real-world evidence, and strategies for more effective biomedical innovation. Bristol Myers Squibbs R&D campus in Redwood City, California focuses on the complexities of the tumor microenvironment. For fiscal 2021, it had a total revenue of $46.4 billion.. Bristol Myers Squibb manufactures This Living Cure Targets only Cancer Cells - Biotech Stock He was a Robert Day Scholar, two-time Bill Gates Investment Asset Management Fellow, and served as CEO of the Student Investment Fund. In January 2019, Chris was nominated as a Commissioner on the National Security Commission on Artificial Intelligence. He has held editorial positions on the British Medical Journal and the Journal of the American Medical Association and is a regular contributor to CNBC. It does not store any personal data. For outside the U.S., visit our global site to report Adverse Events, Product Quality Complaints or submit a Medical Information inquiry. He joins the organization with a 20+ years proven track record of strategic management, go-to-market innovation and industry disruption. Access medical information and resources for U.S. healthcare professionals. While in Vietnam, he was wounded, permanently disabled, and received from this injury a great gift: sympathy for those who are suffering and an appreciation for the capacity of government to save your life. The safety and efficacy of investigational agents and/or investigational uses of approved products have not been established. Ori started his career at Proskauer Rose LLP in New York, NY in 1998 and transferred to Proskauers Boston office in 2011 to lead their private equity and M&A practice in the New England area. Resilience is home to proven experts in all the fields you might expect like biopharmaceutical manufacturing, drug research and development, and policy and regulatory science and some you might not like growth and venture financing, artificial intelligence and machine learning, and software development, cyber security and cloud computing. In 2017 she was elected to the American Academy of Arts and Sciences, was appointed a member of the International Selection Committee for the 2018 Bower Award and Prize for Achievement in Science at the Franklin Institute, and was invited to join the Packard Center Board of Advisors at Johns Hopkins University. In the pipeline Our R&D team Researcher bios Research Publications BMS at June 2022 oncology and hematology congresses BMS at ACTRIMS Forum 2022 BMS at ECCO 2022 BMS at AHA Scientific Sessions 2021 BMS Covid-19 Patient Support Program. This cookie is set by GDPR Cookie Consent plugin. SCCHN = Squamous Cell Carcinoma of the Head & Neck Viet received his BS in Pharmacy from the University of Sciences in Philadelphia and is a certified Six Sigma Black Belt. Necessary cookies are absolutely essential for the website to function properly. He also has a highly distinguished record in public service and academic research. In June 2016, he was named a Living Legend by the Indiana Historical Society. Sandy holds Master of Laws (LL.M.) Mr. Kerrey earned a BS degree in Pharmacy from the University of Nebraska. Prior to Sarvega, Chris was the Chairman and CEO of @stake, the well-known Internet security consulting firm ultimately acquired by Symantec (SYMC). He is vice chair of the board of trustees of The Conference Board, and previously served on the board of Federal Reserve Bank of Cleveland. Gileads acquisition of Kite Pharma for $11.9 billion; Astellas Pharmas acquisition of Xyphos Biosciences and its CAR-T technology for $665 million. Previously, from 2009 to 2013, Pat was Executive Vice President and Global Head of Technical Operations at F. Hoffman-La Roche based in Basel, Switzerland. The site houses computational, clinical and biology research teams as well as dedicated computational research infrastructure and laboratory facilities. Log in below to access your account on BMS Science or Bolder Science. He is Adjunct Assistant Professor at Columbia University, a trustee emeritus of Brown University, and a frequent speaker on leadership and healthcare. HMA = Hypomethylating Agent We also use third-party cookies that help us analyze and understand how you use this website. In 2018, Dr. Davidson was elected to the College of Physicians of Philadelphia. Bristol Myers Squibbs R&D site in the South Lake Union neighborhood of Seattle, Washington is at the center of the Companys discovery, pipeline development and translational research efforts focused on cell therapy and immuno-oncology. In addition, he is on the board of several private companies, including Acepodia, AltruBio, Antheia and Sana Biotechnology. BMS at June 2022 oncology and hematology congresses BMS at ACTRIMS Forum 2022 BMS at ECCO 2022 BMS at AHA Scientific Sessions 2021 BMS at ASH 2021 Media Library with an advanced cell therapy program and a growing early-stage pipeline that expands cell and gene therapy targets and technologies. Get the latest information on our pipeline and currently recruiting clinical trials. Bennett Memorial Lectureship Award from the American Neurological Association in October 2018. He serves as a consultant to and/or director of a number of biotech and pharmaceutical companies and is on several boards of professional journals. She served as president for several multi-billion-dollar Johnson & Johnson companies including Janssen Pharmaceuticals, CNS, and J&J Consumer Healthcare. He is also a Trustee to LivingOnOne, a non-profit impact production studio; WeAreThorn, a NGO which leverages technology to eliminate child trafficking; and the Claremont McKenna College Center for Innovation and Entrepreneurship. + Idecabtagene vicleucel Ori also represented venture capital funds in a wide range of transactions, including investments in portfolio companies and secondary direct transactions. Daniels also serves on the corporate boards of Cerner Corporation and Interactive Intelligence. ESA = Erythropoiesis-Stimulating Agent. At Bristol Myers Squibb, we are driven by the discovery of science that will transform the lives of patients, and our therapeutic pipeline has the potential to do just that. Exploratory Study of Danicamtiv in Patients With Primary Dilated Cardiomyopathy (DCM) Due to Genetic Variants, A Study of Mavacamten in Participants With HFpEF and Elevation of NT-proBNP With or Without Elevation of cTnT (EMBARK-HFpEF), Apixaban for the Acute Treatment of Venous Thromboembolism in Children, Safety and Effectiveness of BMS-986263 in Adults With Compensated Cirrhosis (Liver Disease) From Nonalcoholic Steatohepatitis (NASH), Study to Evaluate Safety and Tolerability of CC-91633 (BMS-986397) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes, A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes, A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia, A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes, Study of CC-96191 in Participants With Relapsed or Refractory Acute Myeloid Leukemia, A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete Remission, A Study to Assess Safety and Tolerability of CC-486 (ONUREG, Oral Azacitidine) in Combination Therapy in Participants With Acute Myeloid Leukemia (AML), A Study to Evaluate Long-term Safety in Subjects Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials. This cookie is set by GDPR Cookie Consent plugin. His seed and early-stage investments include Illumina (ILMN), Alnylam Pharmaceuticals (ALNY), Juno Therapeutics (JUNO, acquired by Celgene-CELG now BMS), Beam Therapeutics (BEAM), Karuna Therapeutics (KRTX), Array BioPharma (ARRY, acquired by Pfizer-PFE), Unity Biotechnology (UBX), Hua Medicine (2552:HK), Vir Biotechnology (VIR), Agios Pharmaceuticals (AGIO), Sage Therapeutics (SAGE), CStone Pharmaceuticals (2616:HK), Gossamer Bio (GOSS), Ikaria (acquired by Mallinckrodt-MNK), Kythera Biopharmaceuticals (KYTH, acquired by Allergan-AGN now ABBV), Receptos (RCPT, acquired by Celgene-CELG now BMS), Aviron (AVIR, acquired by MedImmune-MEDI now AZNCF), Denali Therapeutics (DNLI), Rubius Therapeutics (RUBY), Syros Pharmaceuticals (SYRS), Sana Biotechnology, Lyell Immunopharma, GRAIL, Nutcracker Therapeutics, Bit Bio, Brii Biosciences, Happy Healthcare, Insitro, Maze Therapeutics, Encoded Therapeutics, Encodia, EQRx, Mindstrong, Omniome, Prime Medicine, RBNC Therapeutics, KSQ Therapeutics, SciNeuro Pharmaceuticals, Singular Genomics, Sironax, Sonoma Biotherapeutics, Transcenta Holding, Verve Therapeutics, Volastra Therapeutics, NetBot (acquired by Excite), Bluebird Bio (BLUE), R2 Technology (acquired by Hologic-HOLX), Genomica (GNOM, acquired by Exelixis-EXEL), XenoPort (XNPT, acquired by Arbor Pharmaceuticals), Fate Therapeutics (FATE), Caliper Life Sciences (CALP, acquired by Perkin Elmer-PKI), Trubion Pharmaceuticals (TRBN, acquired by Emergent Biosolutions-EBS), Adolor (ADLR, acquired by Cubist Pharmaceuticals-CBST now MRK), deCODE Genetics (acquired by Amgen-AMGN), Editas (EDIT), 10x Genomics, Semma Therapeutics (acquired by Vertex Pharmaceuticals-VRTX), IDUN Pharmaceuticals (acquired by Pfizer-PFE), Classmates.com (acquired by United Online-UNTD), and Everyday Learning Corporation (acquired by Tribune Corp. now NXST). The BMS R&D site in Seattle is part of BMSs larger Seattle-area presence, which also includes employees working to develop, manufacture and commercialize cell therapies at a BMS cell therapy manufacturing plant in nearby Bothell, WA. Mr. Kerrey served as a U.S. Navy SEAL during the Vietnam War. She serves as a Senior Advisor to the Boston Consulting Group (BCG) and is a guest lecturer at Columbia University Graduate School of Business and Stanford University Graduate School of Business. Outside of Resilience, she is an active volunteer supporting veterans transitioning back into the workforce and ensuring that the Internet is a positive force for good that improves the well-being of people around the world. In this capacity Alex drove therapeutic, platform technology, and personalized healthcare transactions in support of gREDs ambitions to expand its modality expertise, augment computational and data science capabilities and to grow pipeline in regenerative and curative therapies. Sandy played an instrumental role in this growth, and hes personally led a number of Sareptas strategic manufacturing deals. He is a mentor instructor in the Undergraduate Projects Opportunity Program (UPOP) at MIT and is a visiting lecturer at the University College London (UCL). Investigator-initiated clinical research plays an important role in the study of our medicines and the diseases they are intended to treat. Christopher Darby has served as President and CEO of In-Q-Tel since September 2006. She received her undergraduate and MBA degrees from the University of Chicago and is a certified Coach, Compensation Professional and Six Sigma expert. The site focuses on the exploration of novel biology and target concepts such as protein degradation and complex biologics, aiming to better understand and modulate the biological processes that lead to cancer, multiple sclerosis and other diseases with significant unmet needs. Johns Hopkins, Penn Medicine, Independence Blue Cross, and Kaiser Permanente), he sourced and seeded over 40 startups and worked alongside them to get to market with first customers and strategic partners. Get the latest information on our pipeline and currently recruiting clinical trials. While at Celgene, Sandy built the treasury and tax functions before establishing the corporate development department focused on strategic, targeted initiatives including commercial development in emerging markets, acquisitions and licensing, and global manufacturing expansion. He joined Intel in August 2005 with the acquisition of Sarvega, a venture-backed supplier of XML networking and security products, where he served as President and CEO. Clinical and scientific information on BMS medicines, Identify the appropriate Medical Science Liaison in your area with just a few simple clicks, Explore clinical trials to enroll your patient in, Explore Independent Medical Education (IME) programs, Explore areas of interest and independent research opportunities, Explore medicines in our research pipeline, Explore our vast library of journals published by our members and partners in the scientific community, Call our U.S. Medical Information Center for Healthcare Providers, (toll free U.S. only. During his tenure Sareptas employee base grew from around 100 to over 700 employees, its pipeline from nine to over 40 programs in various stages of development, and its footprint of a single location in Cambridge, Massachusetts to over a dozen locations across the U.S. and around the world. Mark Bradley is the chief development officer of Alumis, bringing more than 25 years of experience in the biotechnology industry. At Resilience hes responsible for all things digital including infrastructure, applications/tools/informatics, information security, data science, and software engineering. He is also Executive Chairman of the Minerva Institute for Research and Scholarship, supporting The Minerva Project, an exceptional liberal arts and sciences education. Dr. Pat Yang is one of the most accomplished biotech manufacturing executives and technical operations leaders in the industry. During his six-year tenure at Takeda, the vaccine business grew to over 500 employees and created an industry leading late-stage pipeline of vaccine candidates against dengue, norovirus, and zika. Dr. Schenkein has been a hematologist and medical oncologist for 30 years. Dr. Gottlieb is an aggressive advocate for advancing the health of patients, promoting healthcare access, and driving innovation. Because of our focus on patients, we want to make it easier to find trials relevant to them. These CSRs were created as part of the clinical development process and can be an important part of regulatory application submissions around the world. He currently serves as an adjunct attending physician in hematology at Tufts Medical Center. Dr. McClellan is a former administrator of the Centers for Medicare & Medicaid Services (CMS) and former commissioner of the U.S. Food and Drug Administration (FDA), where he developed and implemented major reforms in health policy. Before joining Flagship, Rahul was the Chief Operating Officer of Takedas Vaccine Business Unit where he was responsible for worldwide vaccine CMC and manufacturing operations. Use the filters below to view trials in specific therapeutic areas or disease areas within the therapeutic areas. Trials are listed alphabetically and by therapeutic area. {"categoryColor":"#595454","phase":[{"name":"1 - Phase I","value":"bms:phase/phase-1","desc":"1"},{"name":"2 - Phase II","value":"bms:phase/phase-2","desc":"2"},{"name":"3 - Phase III","value":"bms:phase/phase-3","desc":"3"}],"listings":[{"compoundname":"
OPDIVO<\/b><\/a><\/sup> Solid Tumors<\/p>\r\n","category":"bms:therapeutiic-area/solid-tumors","subcategory":"bms:tumor/solid-tumors"},{"compoundname":" OPDIVO<\/b><\/a><\/sup> Solid Tumors<\/p>\r\n","category":"bms:therapeutiic-area/solid-tumors","subcategory":"bms:tumor/solid-tumors"},{"compoundname":" OPDIVO<\/b><\/a><\/sup> Peri-adjuvant NSCLC<\/p>\r\n","category":"bms:therapeutiic-area/solid-tumors","subcategory":"bms:tumor/lung"},{"compoundname":" OPDIVO<\/b><\/a><\/sup> Stage 3 Unresectable NSCLC<\/p>\r\n","category":"bms:therapeutiic-area/solid-tumors","subcategory":"bms:tumor/lung"},{"compoundname":" OPDIVO<\/b><\/a><\/sup> Adjuvant<\/p>\r\n","category":"bms:therapeutiic-area/solid-tumors","subcategory":"bms:tumor/hepatocellular-carcinoma"},{"compoundname":" OPDIVO<\/b><\/a><\/sup> 1st<\/sup> line<\/p>\r\n","category":"bms:therapeutiic-area/solid-tumors","subcategory":"bms:tumor/bladder"},{"compoundname":" OPDIVO<\/b><\/a><\/sup> Periadjuvant Muscle Invasive Urothelial Carcinoma<\/p>\r\n","category":"bms:therapeutiic-area/solid-tumors","subcategory":"bms:tumor/bladder"},{"compoundname":" subcutaneous nivolumab + rHuPH20<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":" Advanced 2L<\/p>\r\n","category":"bms:therapeutiic-area/solid-tumors","subcategory":"bms:tumor/renal-cell-carcinoma"},{"compoundname":" OPDIVO<\/b><\/a><\/sup> Adjuvant<\/p>\r\n","category":"bms:therapeutiic-area/solid-tumors","subcategory":"bms:tumor/renal-cell-carcinoma"},{"compoundname":" OPDIVO<\/b><\/a><\/sup> Adjuvant<\/p>\r\n","category":"bms:therapeutiic-area/solid-tumors","subcategory":"bms:tumor/gastric"},{"compoundname":" OPDIVO<\/b><\/a><\/sup> Adjuvant<\/p>\r\n","category":"bms:therapeutiic-area/solid-tumors","subcategory":"bms:tumor/melanoma"},{"compoundname":" Opdualag TM<\/sup><\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":" Adjuvant melanoma<\/p>\r\n","category":"bms:therapeutiic-area/solid-tumors","subcategory":"bms:tumor/melanoma"},{"compoundname":" OPDIVO<\/b><\/a> CRC (MSI-High): 1L+<\/p>\r\n","category":"bms:therapeutiic-area/solid-tumors","subcategory":"bms:tumor/colorectal"},{"compoundname":" OPDIVO<\/b><\/a><\/sup> Metastatic Castration-Resistant 1st Line<\/p>\r\n","category":"bms:therapeutiic-area/solid-tumors","subcategory":"bms:tumor/prostate"},{"compoundname":" OPDIVO<\/b><\/a><\/sup> Metastatic Castration-Resistant 2L<\/p>\r\n","category":"bms:therapeutiic-area/solid-tumors","subcategory":"bms:tumor/prostate"},{"compoundname":" OPDIVO<\/b><\/a><\/sup> Neoadjuvant ER+/HER2-<\/p>\r\n","category":"bms:therapeutiic-area/solid-tumors","subcategory":"bms:tumor/breast"},{"compoundname":" OPDIVO<\/b><\/a><\/sup> Pan-Tumor TMB High<\/p>\r\n","category":"bms:therapeutiic-area/solid-tumors","subcategory":"bms:tumor/solid-tumors"},{"compoundname":" OPDIVO<\/b><\/a><\/sup> Solid Tumors<\/p>\r\n","category":"bms:therapeutiic-area/solid-tumors","subcategory":"bms:tumor/solid-tumors"},{"compoundname":" OPDIVO<\/b><\/a><\/sup> Solid Tumors<\/p>\r\n","category":"bms:therapeutiic-area/solid-tumors","subcategory":"bms:tumor/solid-tumors"},{"compoundname":" Opdualag TM<\/sup>^<\/sup><\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":" Solid Tumors<\/p>\r\n","category":"bms:therapeutiic-area/solid-tumors","subcategory":"bms:tumor/solid-tumors"},{"compoundname":" ABECMA (ide-cel<\/b>+<\/sup>)<\/sup><\/b> Relapsed/Refractory: 3L<\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/multiple-myeloma"},{"compoundname":" ABECMA (ide-cel<\/b>+<\/sup>)<\/sup><\/b> Newly Diagnosed, 2L, 4L+<\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/multiple-myeloma"},{"compoundname":" OPDIVO<\/b><\/a><\/sup> Relapsed/Refractory<\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/multiple-myeloma"},{"compoundname":" iberdomide<\/b> 2L+<\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/multiple-myeloma"},{"compoundname":" iberdomide<\/b> 4L+ & Newly Diagnosed<\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/multiple-myeloma"},{"compoundname":" BCMA ADC<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":" Relapsed/Refractory<\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/multiple-myeloma"},{"compoundname":" mezigdomide(CC-92480)<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":" 2L+<\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/multiple-myeloma"},{"compoundname":" mezigdomide(CC-92480)<\/b><\/p>\r\n","repeat":false,"phaseTag":"bms:phase/phase-2","researcharea":" 2L+, Newly Diagnosed<\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/multiple-myeloma"},{"compoundname":" mezigdomide(CC-92480)<\/b><\/p>\r\n","repeat":false,"phaseTag":"bms:phase/phase-2","researcharea":" 4L+<\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/multiple-myeloma"},{"compoundname":" alnuctamab<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":" Relapsed/Refractory<\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/multiple-myeloma"},{"compoundname":" OPDIVO<\/b><\/a><\/sup> Hematologic Malignancies<\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/hematologic-malignancies"},{"compoundname":" REBLOZYL<\/a><\/b><\/sup> Transfusion Dependent MDS Associated Anemia 1L<\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/myelodysplastic-syndromes"},{"compoundname":" IDHIFA<\/b><\/a><\/sup> 1L<\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/acute-myeloid-leukemia"},{"compoundname":" GSPT1 CELMoD (CC-90009)^<\/sup><\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":" Relapsed/Refractory<\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/acute-myeloid-leukemia"},{"compoundname":" BREYANZI<\/sup><\/b> Chronic Lymphocytic Leukemia (CLL) 3L+<\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/lymphoma"},{"compoundname":" BREYANZI<\/sup><\/b> Marginal Zone Lymphoma (MZL) 3L+<\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/lymphoma"},{"compoundname":" BREYANZI<\/sup><\/b> Follicular Lymphoma 3L+<\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/lymphoma"},{"compoundname":" BREYANZI<\/sup><\/b> Mantle Cell Lymphoma (MCL) 3L+<\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/lymphoma"},{"compoundname":" BET Inhibitor (CC-90010)<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":" Hematologic Malignancies<\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/hematologic-malignancies"},{"compoundname":" A/I CELMoD (CC-99282)^<\/sup><\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-2","researcharea":" Relapsed/Refractory Non-Hodgkin Lymphoma<\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/lymphoma"},{"compoundname":" Anti-SIRP<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":" Hem malignancies<\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/lymphoma"},{"compoundname":" INREBIC<\/b><\/a><\/sup> Previously treated with Ruxolitinib<\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/myelofibrosis"},{"compoundname":" REBLOZYL<\/a><\/b><\/sup> Transfusion dependent MF associated Anemia 1L<\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/myelofibrosis"},{"compoundname":" SOTYKTU<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":" Psoriatic Arthritis<\/p>\r\n","category":"bms:therapeutiic-area/immunology","subcategory":""},{"compoundname":" SOTYKTU<\/b><\/p>\r\n","repeat":false,"phaseTag":"bms:phase/phase-2","researcharea":" Systemic Lupus Erythematosus<\/p>\r\n","category":"bms:therapeutiic-area/immunology","subcategory":""},{"compoundname":" SOTYKTU<\/b><\/p>\r\n","repeat":false,"phaseTag":"bms:phase/phase-2","researcharea":" Crohn's Disease<\/p>\r\n","category":"bms:therapeutiic-area/immunology","subcategory":""},{"compoundname":" SOTYKTU<\/b><\/p>\r\n","repeat":false,"phaseTag":"bms:phase/phase-2","researcharea":" Ulcerative Colitis<\/p>\r\n","category":"bms:therapeutiic-area/immunology","subcategory":""},{"compoundname":" SOTYKTU<\/b><\/p>\r\n","repeat":false,"phaseTag":"bms:phase/phase-2","researcharea":" Discoid Lupus Erythematosus<\/p>\r\n","category":"bms:therapeutiic-area/immunology","subcategory":""},{"compoundname":" cendakimab<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":" Eosinophilic Esophagitis<\/p>\r\n","category":"bms:therapeutiic-area/immunology","subcategory":""},{"compoundname":" cendakimab<\/b><\/p>\r\n","repeat":false,"phaseTag":"bms:phase/phase-2","researcharea":" Atopic Dermatitis<\/p>\r\n","category":"bms:therapeutiic-area/immunology","subcategory":""},{"compoundname":" branebrutinib<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-2","researcharea":" Rheumatoid Arthritis<\/p>\r\n","category":"bms:therapeutiic-area/immunology","subcategory":""},{"compoundname":" TYK2 Inhibitor<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":" Autoimmune Disease<\/p>\r\n","category":"bms:therapeutiic-area/immunology","subcategory":""},{"compoundname":" afimetoran (TLR 7/8Inhibitor)<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-2","researcharea":" Systemic Lupus Erythematosus<\/p>\r\n","category":"bms:therapeutiic-area/immunology","subcategory":""},{"compoundname":" afimetoran (TLR 7/8Inhibitor)<\/b><\/p>\r\n","repeat":false,"phaseTag":"bms:phase/phase-1","researcharea":" Cutaneous Lupus Erythematosus<\/p>\r\n","category":"bms:therapeutiic-area/immunology","subcategory":""},{"compoundname":" NME<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":" Fibrosis<\/p>\r\n","category":"bms:therapeutiic-area/fibrotic-diseases","subcategory":""},{"compoundname":" HSP47<\/sup><\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-2","researcharea":" Non-alcoholic Steatohepatitis<\/p>\r\n","category":"bms:therapeutiic-area/fibrotic-diseases","subcategory":""},{"compoundname":" LPA1 Antagonist<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-2","researcharea":" Pulmonary Fibrosis<\/p>\r\n","category":"bms:therapeutiic-area/fibrotic-diseases","subcategory":""},{"compoundname":" milvexian (FXIa Inhibitor)<\/sup><\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-2","researcharea":" Venous Thromboembolism Prevention<\/p>\r\n","category":"bms:therapeutiic-area/cardiovascular","subcategory":""},{"compoundname":" milvexian (FXIa Inhibitor)<\/sup><\/b><\/p>\r\n","repeat":false,"phaseTag":"bms:phase/phase-2","researcharea":" Secondary Stroke Prevention<\/p>\r\n","category":"bms:therapeutiic-area/cardiovascular","subcategory":""},{"compoundname":" LSD1 Inhibitor^<\/sup><\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":" Solid Tumors<\/p>\r\n","category":"bms:therapeutiic-area/solid-tumors","subcategory":"bms:tumor/solid-tumors"},{"compoundname":" Anti-CTLA-4 NF<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-2","researcharea":" Solid Tumors<\/p>\r\n","category":"bms:therapeutiic-area/solid-tumors","subcategory":"bms:tumor/solid-tumors"},{"compoundname":" MK2 Inhibitor<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-2","researcharea":" Ankylosing Spondylitis<\/p>\r\n","category":"bms:therapeutiic-area/immunology","subcategory":""},{"compoundname":" Anti-CTLA-4 Probody<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-2","researcharea":" Solid Tumors<\/p>\r\n","category":"bms:therapeutiic-area/solid-tumors","subcategory":"bms:tumor/solid-tumors"},{"compoundname":" BET Inhibitor (CC-90010)^<\/sup><\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-2","researcharea":" Solid Tumors<\/p>\r\n","category":"bms:therapeutiic-area/solid-tumors","subcategory":"bms:tumor/solid-tumors"},{"compoundname":" Anti-Fucosyl GM1^<\/sup><\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-2","researcharea":" Solid Tumors<\/p>\r\n","category":"bms:therapeutiic-area/solid-tumors","subcategory":"bms:tumor/solid-tumors"},{"compoundname":" OPDUALAG TM<\/sup><\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-2","researcharea":" Solid Tumors<\/p>\r\n","category":"bms:therapeutiic-area/solid-tumors","subcategory":"bms:tumor/solid-tumors"},{"compoundname":" TIGIT Bispecific<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":" Solid Tumors<\/p>\r\n","category":"bms:therapeutiic-area/solid-tumors","subcategory":"bms:tumor/solid-tumors"},{"compoundname":" farletuzumab-ecteribulin<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-2","researcharea":" Solid Tumors<\/p>\r\n","category":"bms:therapeutiic-area/solid-tumors","subcategory":"bms:tumor/solid-tumors"},{"compoundname":" Anti-TIGIT^<\/sup><\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-2","researcharea":" Solid Tumors<\/p>\r\n","category":"bms:therapeutiic-area/solid-tumors","subcategory":"bms:tumor/solid-tumors"},{"compoundname":" STING Agonist^<\/sup><\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":" Solid Tumors<\/p>\r\n","category":"bms:therapeutiic-area/solid-tumors","subcategory":"bms:tumor/solid-tumors"},{"compoundname":" Anti-SIRP<\/b>^<\/b><\/sup><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":" Solid Tumors<\/p>\r\n","category":"bms:therapeutiic-area/solid-tumors","subcategory":"bms:tumor/solid-tumors"},{"compoundname":" CD3xPSCA Bispecific (Avencell)<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":" Solid Tumors<\/p>\r\n","category":"bms:therapeutiic-area/solid-tumors","subcategory":"bms:tumor/solid-tumors"},{"compoundname":" Anti-IL-8<\/b>^<\/sup><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-2","researcharea":" Solid Tumors<\/p>\r\n","category":"bms:therapeutiic-area/solid-tumors","subcategory":"bms:tumor/solid-tumors"},{"compoundname":" AHR Antagonist <\/b>^<\/b><\/sup>(Ikena)<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":" Solid Tumors<\/p>\r\n","category":"bms:therapeutiic-area/solid-tumors","subcategory":"bms:tumor/solid-tumors"},{"compoundname":" Anti-CTLA-4 NF Probody^<\/sup><\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":" Solid Tumors<\/p>\r\n","category":"bms:therapeutiic-area/solid-tumors","subcategory":"bms:tumor/solid-tumors"},{"compoundname":" IL2-CD25<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":" Autoimmune Disease<\/p>\r\n","category":"bms:therapeutiic-area/immunology","subcategory":""},{"compoundname":" Anti-CD40<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":" Autoimmune Disease<\/p>\r\n","category":"bms:therapeutiic-area/immunology","subcategory":""},{"compoundname":" ZEPOSIA<\/a><\/sup><\/b> Crohn\u2019s Disease<\/p>\r\n","category":"bms:therapeutiic-area/immunology","subcategory":""},{"compoundname":" AR-LDD<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":" Solid Tumors<\/p>\r\n","category":"bms:therapeutiic-area/solid-tumors","subcategory":"bms:tumor/solid-tumors"},{"compoundname":" Anti-NKG2A^<\/sup><\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":" Solid Tumors<\/p>\r\n","category":"bms:therapeutiic-area/solid-tumors","subcategory":"bms:tumor/solid-tumors"},{"compoundname":" FAAH/MGLL Dual Inhibitor<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":" Neuroscience<\/p>\r\n","category":"bms:therapeutiic-area/neuroscience","subcategory":""},{"compoundname":" FXIa Inhibitor <\/sup><\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":" Thrombotic Disorders<\/p>\r\n","category":"bms:therapeutiic-area/cardiovascular","subcategory":""},{"compoundname":" iberdomide<\/b> DLBCL 1L<\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/lymphoma"},{"compoundname":" iberdomide<\/b> RR NHL, LBCL, FL 3L+<\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/lymphoma"},{"compoundname":" TGF Inhibitor^<\/sup><\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":" Solid Tumors<\/p>\r\n","category":"bms:therapeutiic-area/solid-tumors","subcategory":"bms:tumor/solid-tumors"},{"compoundname":" IL-12 Fc^<\/sup><\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":" Solid Tumors<\/p>\r\n","category":"bms:therapeutiic-area/solid-tumors","subcategory":"bms:tumor/solid-tumors"},{"compoundname":" GPRC5D CAR T<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":" Relapsed/Refractory<\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/multiple-myeloma"},{"compoundname":" BET Inhibitor (BMS-986158)<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-2","researcharea":" Hematologic Malignancies<\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/hematologic-malignancies"},{"compoundname":" CAMZYOS <\/u>TM<\/sup><\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":" Non-obstructive Hypertrophic Cardiomyopathy<\/p>\r\n","category":"bms:therapeutiic-area/cardiovascular","subcategory":""},{"compoundname":" CAMZYOS <\/u>TM<\/sup><\/b><\/p>\r\n","repeat":false,"phaseTag":"bms:phase/phase-2","researcharea":" Heart Failure with Preserved Ejection Fraction<\/p>\r\n","category":"bms:therapeutiic-area/cardiovascular","subcategory":""},{"compoundname":" danicamtiv<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-2","researcharea":" Genetic Dilated Cardiomyopathy<\/p>\r\n","category":"bms:therapeutiic-area/cardiovascular","subcategory":""},{"compoundname":" Cardiac Myosin Inhibitor (MYK-224)<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-2","researcharea":" Obstructive Hypertrophic Cardiomyopathy <\/p>\r\n","category":"bms:therapeutiic-area/cardiovascular","subcategory":""},{"compoundname":" CD33 NKE<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":" Relapsed/Refractory<\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/multiple-myeloma"},{"compoundname":" CD47xCD20<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":" Non-Hodgkin Lymphoma<\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/lymphoma"},{"compoundname":" Anti-CCR8^<\/sup><\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":" Solid Tumors<\/p>\r\n","category":"bms:therapeutiic-area/solid-tumors","subcategory":"bms:tumor/solid-tumors"},{"compoundname":" CK1 Degrader<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":" Hematologic Malignancies<\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/hematologic-malignancies"},{"compoundname":" ORENCIA<\/sup> (abatacept)<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-2","researcharea":" COVID-19 treatment<\/p>\r\n","category":"bms:therapeutiic-area/covid-19","subcategory":""},{"compoundname":" Anti-Tau (Prothena)<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":" Neuroscience<\/p>\r\n","category":"bms:therapeutiic-area/neuroscience","subcategory":""},{"compoundname":" BTK Inhibitor<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":" Neuroscience<\/p>\r\n","category":"bms:therapeutiic-area/neuroscience","subcategory":""},{"compoundname":" BCMA NKE<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":" Relapsed/Refractory<\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/multiple-myeloma"},{"compoundname":" ROR1 CAR T<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":" Hematologic Malignancies<\/p>\r\n","category":"bms:therapeutiic-area/hematology","subcategory":"bms:tumor/hematologic-malignancies"},{"compoundname":" eIF2b Activator<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":" Neuroscience<\/p>\r\n","category":"bms:therapeutiic-area/neuroscience","subcategory":""},{"compoundname":" MAGE A4/8 TCER <\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":" Solid Tumors<\/p>\r\n","category":"bms:therapeutiic-area/solid-tumors","subcategory":"bms:tumor/solid-tumors"},{"compoundname":" Anti-ILT4^<\/sup><\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":" Solid Tumors<\/p>\r\n","category":"bms:therapeutiic-area/solid-tumors","subcategory":"bms:tumor/solid-tumors"},{"compoundname":" subcutaneous nivolumab + rHuPH20<\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":" Adjuvant<\/p>\r\n","category":"bms:therapeutiic-area/solid-tumors","subcategory":"bms:tumor/melanoma"},{"compoundname":" OpdualagTM<\/sup><\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":" 2L + Microsatellite Stable Metastatic Colorectal Cancer<\/p>\r\n","category":"bms:therapeutiic-area/solid-tumors","subcategory":"bms:tumor/colorectal"},{"compoundname":" DGK Inhibitor<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":" Solid Tumors<\/p>\r\n","category":"bms:therapeutiic-area/solid-tumors","subcategory":"bms:tumor/solid-tumors"},{"compoundname":" nivolumab+relatlimab<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-2","researcharea":" 2L<\/p>\r\n","category":"bms:therapeutiic-area/solid-tumors","subcategory":"bms:tumor/hepatocellular-carcinoma"},{"compoundname":" nivolumab+relatlimab<\/b><\/p>\r\n","repeat":false,"phaseTag":"bms:phase/phase-2","researcharea":" 1L<\/p>\r\n","category":"bms:therapeutiic-area/solid-tumors","subcategory":"bms:tumor/hepatocellular-carcinoma"},{"compoundname":" Anti-RIPK1 Inhibitor<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":" Autoimmune Disease<\/p>\r\n","category":"bms:therapeutiic-area/immunology","subcategory":""},{"compoundname":" nivolumab+relatlimab<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-2","researcharea":" Stage IV NSCLC 1L<\/p>\r\n","category":"bms:therapeutiic-area/solid-tumors","subcategory":"bms:tumor/lung"},{"compoundname":" OPDIVO<\/b><\/a> Colorectal: 2L<\/p>\r\n","category":"bms:therapeutiic-area/solid-tumors","subcategory":"bms:tumor/colorectal"},{"compoundname":" SHP2 Inhibitor^<\/sup><\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":" Solid Tumors<\/p>\r\n","category":"bms:therapeutiic-area/solid-tumors","subcategory":"bms:tumor/solid-tumors"},{"compoundname":" JNK Inhibitor<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":" Advanced Solid Tumors<\/p>\r\n","category":"bms:therapeutiic-area/solid-tumors","subcategory":"bms:tumor/solid-tumors"},{"compoundname":" repotrectinib<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-2","researcharea":" ROS1 NSCLC<\/p>\r\n","category":"bms:therapeutiic-area/solid-tumors","subcategory":"bms:tumor/lung"},{"compoundname":" repotrectinib<\/b><\/p>\r\n","repeat":false,"phaseTag":"bms:phase/phase-2","researcharea":" NTRK NSCLC<\/p>\r\n","category":"bms:therapeutiic-area/solid-tumors","subcategory":"bms:tumor/lung"},{"compoundname":" OPDIVO<\/sup>(nivolumab) +YERVOY<\/sup>(ipilimumab)<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":" 1L<\/p>\r\n","category":"bms:therapeutiic-area/solid-tumors","subcategory":"bms:tumor/hepatocellular-carcinoma"}],"therapeuticarea":[{"color":"#dbc5c5","name":"bms:therapeutiic-area/cardiovascular","value":"Cardiovascular"},{"color":"#EFD9D8","name":"bms:therapeutiic-area/covid-19","value":"Covid-19"},{"color":"#ffeccd","name":"bms:therapeutiic-area/fibrotic-diseases","value":"Fibrotic Diseases"},{"color":"#fedcca","name":"bms:therapeutiic-area/hematology","list":[{"name":"bms:tumor/acute-myeloid-leukemia","value":"Acute Myeloid Leukemia (AML)"},{"name":"bms:tumor/hematologic-malignancies","value":"Hematologic Malignancies"},{"name":"bms:tumor/lymphoma","value":"Lymphoma"},{"name":"bms:tumor/multiple-myeloma","value":"Multiple Myeloma (MM)"},{"name":"bms:tumor/myelodysplastic-syndromes","value":"Myelodysplastic Syndromes (MDS)"},{"name":"bms:tumor/myelofibrosis","value":"Myelofibrosis (MF)"}],"value":"Hematology"},{"color":"#c5ffe6","name":"bms:therapeutiic-area/immunology","value":"Immunology"},{"color":"#d8ddd1","name":"bms:therapeutiic-area/neuroscience","value":"Neuroscience"},{"color":"#c0f2fb","name":"bms:therapeutiic-area/solid-tumors","list":[{"name":"bms:tumor/bladder","value":"Bladder"},{"name":"bms:tumor/breast","value":"Breast"},{"name":"bms:tumor/colorectal","value":"Colorectal"},{"name":"bms:tumor/gastric","value":"Gastric"},{"name":"bms:tumor/hepatocellular-carcinoma","value":"Hepatocellular Carcinoma (HCC)"},{"name":"bms:tumor/lung","value":"Lung"},{"name":"bms:tumor/melanoma","value":"Melanoma"},{"name":"bms:tumor/prostate","value":"Prostate"},{"name":"bms:tumor/renal-cell-carcinoma","value":"Renal Cell Carcinoma (RCC)"},{"name":"bms:tumor/solid-tumors","value":"Solid Tumors"}],"value":"Solid Tumors"}],"subCategoryColor":"#A69F9F"}, Risk Evaluation and Mitigation Strategies (REMS), Pre-Approval Access to Investigational Medicines, Areas of Interest & Competitive Research Grants, The Thomas O. Daniel Research Incubator and Collaboration Center, Acquisition FAQs for Celgene Shareholders, Acquisition-related information for Celgene shareholders, Unsubscribe to News Email Alerts - Bristol Myers Squibb, Subscribe to New Email Alerts - Bristol Myers Squibb, BMS at June 2022 oncology and hematology congresses, Committed to creating a better future for cancer patients, People & Business Resource Groups leadership team, Our Commitment to Equal Employment Opportunity, Access to Medicines in the Developing World, UK-CA Slavery and Human Trafficking Statement (PDF), Our Commitment to Global Inclusion & Diversity>. Texas State Fall 2022 Academic Calendar,
Taylor Swift Folklore Quiz,
Film Festival Names Ideas,
How To Apply Eyelash Primer,
Watertown Persian Restaurant,
University Of Kentucky Student Id Number,
Compound Sentence Worksheet Pdf,
H-e-b Crawfish Boil 2022,
Boardman, Ohio Houses For Rent,
\r\n(nivolumab) +<\/b>
\r\nYERVOY<\/b><\/a><\/sup>
\r\n(ipilimumab)<\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-2","researcharea":"
\r\n(nivolumab) +<\/b>
\r\nYERVOY<\/b><\/a><\/sup>
\r\n(ipilimumab)<\/p>\r\n","repeat":false,"phaseTag":"bms:phase/phase-1","researcharea":"
\r\n(nivolumab)<\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":"
\r\n(nivolumab) +<\/b>
\r\nYERVOY<\/b><\/a><\/sup>
\r\n(ipilimumab)<\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":"
\r\n(nivolumab)<\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":"
\r\n(nivolumab) +<\/b>
\r\nYERVOY<\/b><\/a><\/sup>
\r\n(ipilimumab)<\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":"
\r\n(nivolumab)<\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":"
\r\n(nivolumab) +<\/b>
\r\nYERVOY<\/b><\/a><\/sup>
\r\n(ipilimumab)<\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":"
\r\n(nivolumab)<\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":"
\r\n(nivolumab)<\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":"
\r\n(nivolumab)+<\/b>
\r\nYERVOY<\/b><\/a>
\r\n(ipilimumab)<\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":"
\r\n(nivolumab)<\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":"
\r\n(nivolumab) +<\/b>
\r\nYERVOY<\/b><\/a><\/sup>
\r\n(ipilimumab)<\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-2","researcharea":"
\r\n(nivolumab) +<\/b>
\r\n CDK4/6 Inhibitor<\/b>
\r\n<\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-2","researcharea":"
\r\n(nivolumab)<\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-2","researcharea":"
\r\n(nivolumab)<\/p>\r\n","repeat":false,"phaseTag":"bms:phase/phase-2","researcharea":"
\r\n(nivolumab)<\/p>\r\n","repeat":false,"phaseTag":"bms:phase/phase-1","researcharea":"
\r\n<\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":"
\r\n<\/p>\r\n","repeat":false,"phaseTag":"bms:phase/phase-2","researcharea":"
\r\n(nivolumab) +<\/b>
\r\nEMPLICITI<\/b><\/a><\/sup>
\r\n(elotuzumab)<\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-2","researcharea":"
\r\n<\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":"
\r\n<\/p>\r\n","repeat":false,"phaseTag":"bms:phase/phase-2","researcharea":"
\r\n(nivolumab)<\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"
\r\n(luspatercept-aamt)<\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":"
\r\n(enasidenib)<\/b><\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-2","researcharea":"
\r\n(liso-cel*<\/b>)<\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-2","researcharea":"
\r\n(liso-cel*<\/b>)<\/p>\r\n","repeat":false,"phaseTag":"bms:phase/phase-2","researcharea":"
\r\n(liso-cel*<\/b>)<\/p>\r\n","repeat":false,"phaseTag":"bms:phase/phase-2","researcharea":"
\r\n(liso-cel*<\/b>)<\/p>\r\n","repeat":false,"phaseTag":"bms:phase/phase-2","researcharea":"
\r\n(fedratinib)<\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":"
\r\n(luspatercept-aamt)<\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":"
\r\n(ozanimod)<\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-3","researcharea":"
\r\n<\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-1","researcharea":"
\r\n<\/p>\r\n","repeat":false,"phaseTag":"bms:phase/phase-1","researcharea":"
\r\n(nivolumab)
\r\n<\/p>\r\n","repeat":true,"phaseTag":"bms:phase/phase-2","researcharea":"